Source: Annual Congress 2010 - New mechanisms in lung development, acute and chronic lung diseases
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Raizada (Gainesville, United States Of America). LSC 2010 Abstract: Potential of ACE2 as a therapeutic target for pulmonary hypertension. Eur Respir J 2010; 36: Suppl. 54, 2196

Member's Comments

No comment yet.

Related content which might interest you: Oral presentation: Potential of ACE2 as a therapeutic target for pulmonary hypertension Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010 Fibrocytes: potential new therapeutic targets for pulmonary hypertension? Source: Eur Respir J 2010; 36: 1232-1235 Year: 2010 Pulmonary hypertension in ILDs: novel therapeutic data Source: International Congress 2019 – Lungs in the fog Year: 2019 Beta 3 adrenoceptor: a potential therapeutic target for pulmonary arterial hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 PSGR olfactory receptor: A new potential target in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Thrombospondin-1 in pulmonary hypertension: A potential indicator of shearstress Source: Annual Congress 2010 - Pulmonary circulation III Year: 2010 Novel therapeutic perspectives in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: 193-194 Year: 2003 Lung transplantation for pulmonary hypertension: the impact of new drug therapies Source: Annual Congress 2004 - Lung transplantation: new insights in advanced lung disease and new drug developments - do they impact on selection criteria? Year: 2004 Oral delivery of transplastomic plant derived angiotensin converting enzyme2 - a novel approach for pulmonary hypertension therapeutics Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Pulmonary hypertension: where are we in 2007? Source: ERS Live 2007 Year: 2007 Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications Source: Eur Respir J 2010; 35: 418-425 Year: 2010 Role of microRNA 17/92 cluster and microRNA 21 in the pathogenesis of pulmonary hypertension – Novel therapeutic targets Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 LSC 2010 Abstract: Overexpression of Ang-(1-7)-fusion protein in the lungs prevents pulmonary fibrosis and accompanying pulmonary hypertension Source: Annual Congress 2010 - Pre-clinical models of airways disease Year: 2010 Phosphodiesterase inhibitors as promising therapies for cigarette smoke-induced emphysema and pulmonary hypertension (PH) in mice Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension Source: Eur Respir J, 51 (6) 1702638; 10.1183/13993003.02638-2017 Year: 2018 Seeking the right targets: gene therapy advances in pulmonary arterial hypertension Source: Eur Respir J 2012; 39: 235-237 Year: 2012 Targeting HIF2a-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension Source: Eur Respir J, 57 (3) 1902061; 10.1183/13993003.02061-2019 Year: 2021 Analysis of miRNA profile in circulating microparticles of patients with pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015